

# DEPTH OF BIOLOGY

## Unit - 3

Reproductive toxicology studies, Male reproductive toxicity 12 studies, female reproductive studies (segment I and segment III) teratogenecity studies (segment II)

Genotoxicity studies (Ames Test, in vitro and in vivo Micronucleus and Chromosomal aberrations studies)

In vivo carcinogenicity studies

## Reproductive toxicology studies

Reproductive toxicology is the study of adverse effects of chemicals, drugs, or environmental agents on the reproductive system of both males and females, and on the developing embryo/fetus.

It helps to identify risks of infertility, developmental defects, pregnancy loss, and congenital anomalies.

## Why It Is Important-

The reproductive system is highly sensitive to toxic insults because it involves complex processes like gametogenesis, fertilization, embryogenesis, organogenesis, and postnatal maturation.

Even small disturbances can lead to:

Infertility (failure to conceive in males or females)

Pregnancy loss (early embryonic death, abortion, stillbirth)

Teratogenic effects (congenital malformations, structural abnormalities)

Growth retardation (intrauterine growth restriction, low birth weight)

Functional deficits (behavioral abnormalities, learning deficits in offspring)

## Historical Background-

The field gained importance after the Thalidomide tragedy (1960s), where a sedative given to pregnant women caused phocomelia (limb deformities) in thousands of babies.

Since then, reproductive and developmental toxicity testing became mandatory for all new drugs and chemicals before approval.



## Objectives of Reproductive Toxicology Studies-

To identify and characterize potential hazards of substances on reproduction.

To determine dose-response relationship for reproductive toxicity.

To provide data for risk assessment in humans.

To establish safe exposure limits for pregnant women and individuals of reproductive age.

To guide regulatory labeling of drugs (e.g., pregnancy warnings, contraindications).

# DEPTH OF BIOLOGY

## Male reproductive toxicity 12 studies

Male reproductive toxicity refers to adverse effects of drugs, chemicals, or environmental agents on the structure and function of male reproductive organs, spermatogenesis, hormonal balance, and fertility.

*The male reproductive system is highly sensitive because:*

- Spermatogenesis is continuous (takes ~48–52 days in humans, 48 days in rats).
- Germ cells rapidly divide → highly vulnerable to toxins, mutagens, radiation.
- Dependence on hormonal regulation (HPT axis).

Toxicants may cause: reduced sperm count, abnormal sperm morphology, impaired mating, infertility, or heritable genetic damage.

# DEPTH OF BIOLOGY

## Detailed Studies (12 Key Endpoints)

### 1. Fertility Studies (Mating & Impregnation)-

**Purpose:** Assess ability of treated males to fertilize untreated females.

**Method:**

Treated males are cohabited with proven-fertile females.

Monitor copulatory plug (mating evidence) and pregnancy rates.

**Parameters:** Fertility index, pregnancy success, number of implantation sites.

**Significance:** Functional measure of overall reproductive competence.

## 2. Testicular Histopathology-

**Purpose:** Examine structural damage to testes.

**Method:**

Testes fixed, sectioned, and stained (H&E, PAS).

Evaluate seminiferous tubules, germ cells, Sertoli & Leydig cells.

**Findings:** Germ cell depletion, tubular atrophy, degeneration, interstitial fibrosis.

**Significance:** Detects site of damage (e.g., germ cells vs interstitial cells).

## 3. Sperm Count

**Purpose:** Estimate total sperm production.

**Method:**

Epididymal sperm suspension prepared, counted using hemocytometer or CASA (Computer-Assisted Sperm Analysis).

**Parameters:** Sperm density per mL and per epididymis/testis.

**Significance:** Reduction indicates suppression of spermatogenesis.

## 4. Sperm Motility Test-

**Purpose:** Assess sperm ability to move effectively.

**Method:**

Microscopic observation (phase contrast).

CASA for % motility, velocity, path straightness.

**Parameters:** % motile sperm, progressive vs non-progressive motility.

**Significance:** Poor motility = failure to reach and fertilize ovum.

## 5. Sperm Morphology Analysis-

**Purpose:** Detect structural abnormalities.

**Method:**

Sperm stained (eosin–nigrosin, Papanicolaou).

Microscopic evaluation of 200–500 sperm per animal.

**Findings:** Head defects (double head, amorphous head), midpiece defects, tail defects.

**Significance:** Abnormal morphology strongly correlates with infertility.

## 6. Daily Sperm Production (DSP)-

**Purpose:** Quantify rate of sperm generation per day.

**Method:**

Homogenize testis → count elongated spermatids → calculate DSP using known duration of spermatid development.

**Significance:** Sensitive marker of toxicant-induced spermatogenic arrest.

## 7. Epididymal Sperm Maturation Test-

**Purpose:** Evaluate sperm maturation & functional competence.

**Method:**

Sperm collected from caput and cauda epididymis.

**Tests:** acrosome reaction assay, capacitation assay.

**Parameters:** % mature sperm, acrosome integrity, ability to bind ovum.

**Significance:** Detects toxicants impairing post-testicular sperm maturation.

## 8. Hormonal Assays-

**Purpose:** Evaluate endocrine regulation of reproduction.

**Method:**

Serum/plasma levels of testosterone, LH, FSH, inhibin B, estradiol measured (RIA, ELISA, LC-MS/MS).

**Findings:**

↓ Testosterone → Leydig cell toxicity.

↑ FSH, LH → impaired spermatogenesis (feedback failure).

**Significance:** Distinguishes testicular vs pituitary/hypothalamic origin of toxicity.

## 9. Accessory Sex Gland Evaluation-

Purpose: Assess androgen-dependent organs.

Organs: Prostate, seminal vesicles, coagulating glands, bulbourethral glands.

Method: Organ weight, histopathology, secretion analysis.

Significance: Reduction in size/weight indicates androgen deficiency or anti-androgenic effect.

## 10. DNA Integrity Tests-

**Purpose:** Detect DNA/chromatin damage in sperm.

**Techniques:**

Comet assay (single-cell gel electrophoresis)

Sperm Chromatin Structure Assay (SCSA)

TUNEL assay (DNA fragmentation)

**Significance:** Detects mutagenic and heritable effects, which may not be seen in morphology or motility.

## 11. Mating Behavior Studies-

**Purpose:** Examine neuroendocrine and behavioral aspects of reproduction.

**Parameters measured:**

Mounting latency & frequency

Intrusion latency & frequency

Ejaculation latency

**Significance:** Helps differentiate between endocrine/neurological toxicity vs direct gonadal toxicity.

## 12. Fertility & Reproductive Performance Test (Functional Test)-

**Purpose:** Gold standard for reproductive toxicity.

**Method:**

Treated males are paired with untreated females over multiple cycles.

Pregnancy rate, litter size, pup viability monitored.

**Significance:** Provides overall fertility outcome (integrates all endpoints).

## Female reproductive studies (segment I and segment III)

### Introduction-

Female reproductive toxicity studies assess the adverse effects of drugs, chemicals, or xenobiotics on female fertility, pregnancy, parturition, lactation, and development of offspring.

According to ICH and OECD guidelines, reproductive toxicity studies are divided into 3 segments:

Segment I → Fertility & early embryonic development

Segment II → Embryo-fetal development (teratogenicity)

Segment III → Pre- and postnatal development

## Segment I: Fertility & Early Embryonic Development Studies–

### Purpose

To determine if a test substance affects female reproductive performance before and during pregnancy.

To evaluate early embryonic development until implantation.

### Design

Test animals: Usually rats (due to short reproductive cycle, high fertility rate).

### Dosing period:

Females: From at least 2–4 weeks before mating through mating until implantation (gestation day 6–7 in rodents).

Males (if included): At least 70 days before mating (covers spermatogenesis).

Mating: Treated females mated with untreated fertile males (or vice versa).

## *Parameters Studied-*

- Estrous cycle regularity (proestrus, estrus, diestrus).
- Mating success & fertility index.
- Number of corpora lutea (ovulation marker).
- Number of implantations in uterus.
- Pre-implantation loss (difference between corpora lutea and implantations).
- Post-implantation loss (difference between implantations and live embryos).
- Early embryonic development (embryo viability at implantation stage).

## *Significance*

*Detects female infertility due to:*

*Disruption of ovulation or fertilization.*

*Failure of embryo transport.*

*Impaired implantation.*

## Segment III: Pre- & Postnatal Development Studies-

### *Purpose*

To evaluate effects of test substance on pregnancy, parturition, lactation, and development of offspring (F1 generation).

Also examines potential impact on second generation fertility (F2).

### *Design*

Test animals: Rat is preferred.

Dosing period:

Pregnant females are dosed from implantation (gestation day 6) → through pregnancy → delivery → lactation until weaning of pups.

**Follow-up:** Offspring are observed until maturity; sometimes mated to produce F2 generation.

# DEPTH OF BIOLOGY

Parameters Studied –

In Mothers ( $F_0$  generation):

Duration of pregnancy & parturition (labor difficulties).

Maternal behavior (nursing, grooming).

Mortality during pregnancy/lactation.

# DEPTH OF BIOLOGY

In Offspring (F1 generation):

Litter size (number of live and dead pups).

Pup survival rates (neonatal mortality, stillbirths).

Growth and physical development (body weight, eye opening, hair growth, tooth eruption).

Neurobehavioral development (locomotor activity, reflexes, learning ability, memory tests).

Pubertal development (vaginal opening, estrous cyclicity in females).

Reproductive performance of F1 animals (fertility testing).

Transgenerational effects: Sometimes F1 animals are mated → F2 generation observed.

## Significance -

Detects toxicants causing:

Pregnancy loss, dystocia (difficult labor).

Poor lactation or maternal care.

Reduced neonatal viability.

Growth retardation, behavioral deficits.

Impaired fertility in next generation.

## Conclusion

Segment I (female fertility & early embryonic development): Identifies effects on ovulation, fertilization, implantation, and early embryo survival.

Segment III (pre/postnatal development): Assesses pregnancy maintenance, parturition, lactation, offspring survival, growth, and reproductive function of progeny.

Together, they provide a complete picture of female reproductive safety across multiple life stages.

## Teratogenecity studies (segment II)

### Introduction

Teratogenicity = the ability of a drug, chemical, or environmental agent to induce structural malformations (congenital anomalies) in a developing embryo/fetus. The science of detecting such effects is called teratology (from Greek teras = monster, logos = study).

The critical period of susceptibility = organogenesis (day 13–16 in rats, day 6–15 in mice, day 6–18 in rabbits, 3–8 weeks in humans).

The thalidomide tragedy (1960s) highlighted the importance of teratogenicity testing → caused phocomelia (limb deformities) in >10,000 babies.

## 2. Purpose of Segment II Studies-

*To detect whether a test substance causes:*

Embryotoxicity (embryo death/resorption).

Fetotoxicity (growth retardation, low body weight).

Teratogenicity (malformations of organs/skeleton).

Variations (minor anomalies, often reversible).

To determine dose-response relationship for developmental toxicity.

To provide safety data for regulatory labeling and clinical risk assessment in pregnancy.

## *3. Study Design-*

Test animals: At least 2 species →

1 rodent (rat or mouse)

1 non-rodent (rabbit is preferred)

Dosing schedule:

Females are dosed daily during organogenesis (e.g., GD 6–15 in rats, GD 6–18 in rabbits).

Termination:

Animals sacrificed before delivery (rat GD 20–21, rabbit GD 28–29).

Fetuses removed and examined.

## *4. Parameters Studied*

### Maternal Observations

Clinical signs of toxicity (weight loss, reduced food intake).

Maternal mortality.

Body weight gain, gravid uterine weight.

### Embryo/Fetal Observations

1. Implantations (successful embryo attachment).
2. Resorptions (early or late embryonic death).
3. Fetal viability (live vs dead fetuses).
4. Fetal body weight (detects growth retardation).
5. Sex ratio of fetuses.

## Malformation Studies-

External malformations: cleft palate, limb deformities, microcephaly.

Visceral malformations: cardiac defects, renal agenesis.

Skeletal malformations: delayed ossification, extra ribs, fused vertebrae.

## Techniques Used

External exam under stereomicroscope.

Visceral exam: Wilson's sectioning, microdissection.

Skeletal exam: Alizarin red staining for ossification defects.

## *5. Types of Developmental Toxicity-*

Embryotoxicity → death before organogenesis.

Fetotoxicity → growth retardation after organogenesis.

Teratogenicity → structural malformations.

Variations → minor anomalies, often species-specific, may not persist.

## *6. Significance-*

Essential for drug approval before human use.

Ensures pregnant women are protected from teratogens.

Provides data for pregnancy labeling (FDA → PLLR rule).

Prevents disasters like thalidomide or isotretinoin-induced birth defects.

## 7. Conclusion-

Segment II studies are critical to evaluate safety of drugs/chemicals in pregnancy.

They detect malformations, growth retardation, fetal death, and provide a scientific basis for safe drug use in women of childbearing age.

## Genotoxicity studies

(Ames Test, in vitro and in vivo Micronucleus and Chromosomal aberrations studies)

### *1. Introduction-*

**Genotoxicity:** The ability of a substance to damage the genetic material (DNA) in cells  
→ may lead to mutations, chromosomal breaks, cancer, or heritable genetic defects.

Genotoxicity testing is essential to detect potential mutagenic and carcinogenic risks of pharmaceuticals, chemicals, food additives, and pesticides.

Conducted in vitro (cell culture, bacteria) and in vivo (animals).

## 2. Ames Test (Bacterial Reverse Mutation Test)-

### Purpose

Detects point mutations (base-pair substitutions or frame-shift mutations) in DNA.

### Principle

Uses mutant strains of *Salmonella typhimurium* (histidine-dependent) or *E. coli* (tryptophan-dependent).

These strains cannot grow without histidine ( $\text{His}^-$ )  $\rightarrow$  if the test substance causes a mutation that restores histidine synthesis ( $\text{His}^+$  revertant), colonies grow on histidine-free medium.

## Method-

Mutant bacterial strains (His<sup>-</sup>) are mixed with test chemical  $\pm$  metabolic activation system (S9 fraction from rat liver microsomes, mimics mammalian metabolism).

Plated on agar lacking histidine.

Count number of revertant colonies.

## Result

↑ Number of revertant colonies vs control = mutagenic potential.

## Significance

First-line screen for mutagenicity.

Rapid, inexpensive, sensitive.

## 3. Micronucleus Test-

### Purpose

Detects chromosome breakage (clastogenicity) or chromosome mis-segregation (aneugenicity) during cell division.

### Principle

When chromosomes/chromatids are damaged or fail to segregate properly → small micronuclei (extra-nuclear bodies) form in the cytoplasm of daughter cells.

## Types-

### a) In Vitro Micronucleus Assay-

Cells used: Cultured mammalian cells (e.g., human lymphocytes, CHO cells).

### Procedure:

Cells exposed to test chemical  $\pm$  metabolic activation (S9).

Cytokinesis-block technique (cytochalasin B) used  $\rightarrow$  ensures only dividing cells are analyzed.

Micronuclei scored under microscope.

## b) In Vivo Micronucleus Assay-

Animals used: Mice or rats.

Procedure:

Test substance administered.

Bone marrow (polychromatic erythrocytes, PCEs) or peripheral blood cells examined.

Micronucleated PCEs counted.

Significance-

Detects chromosomal damage in vitro and in vivo.

Recommended by OECD (TG 487 for in vitro; TG 474 for in vivo).

## 4. Chromosomal Aberration Test-

### Purpose

Detects structural changes in chromosomes caused by chemicals.

### Principle

If DNA is damaged, cells may show chromatid breaks, gaps, translocations, deletions, dicentrics, ring chromosomes.

## Types-

### a) In Vitro Chromosomal Aberration Test

Cells used: Human peripheral blood lymphocytes, CHO (Chinese Hamster Ovary), V79 cells.

### Procedure:

Cells exposed to test substance  $\pm$  metabolic activation.

Arrested in metaphase using colchicine.

Chromosomes stained (Giemsa) and examined microscopically.

## b) In Vivo Chromosomal Aberration Test-

Animals used: Mice or rats.

Procedure:

Test chemical administered.

Bone marrow or germ cells collected.

Chromosomal aberrations analyzed in metaphase spreads.

Significance

Detects clastogenic agents (those causing DNA/chromosomal breakage).

OECD TG 473 (in vitro), TG 475 (in vivo).

## 5. Importance of Genotoxicity Testing-

Identifies mutagenic, clastogenic, aneugenic substances.

Prevents approval of carcinogenic or heritable mutagenic drugs/chemicals.

Regulatory requirement (ICH S2(R1), OECD guidelines).

Basis for drug labeling, risk assessment, and safety in humans.

## 6. Conclusion-

Ames test → detects point mutations (gene-level).

Micronucleus assay → detects chromosome breaks/loss.

Chromosomal aberration test → detects structural chromosomal changes.

Together, these provide a comprehensive evaluation of genotoxic potential, both in vitro and in vivo.

## In vivo carcinogenicity studies

### 1. Introduction

Carcinogenicity = ability of a chemical/drug to induce neoplasia (benign or malignant tumors).

Carcinogenicity testing is mandatory for drugs intended for long-term human use ( $\geq 6$  months), food additives, pesticides, and environmental chemicals.

These studies are conducted in rodents (rats, mice) over most of their lifespan to evaluate tumor incidence.

Regulatory guidelines: OECD (TG 451–453), ICH S1, EPA, Schedule Y.

## 2. Purpose of Carcinogenicity Studies-

To identify whether a substance has oncogenic potential.

To determine dose-response relationship of tumor development.

To assess target organ(s) of carcinogenicity.

To provide data for human risk assessment and labeling.

### Regulatory Guidelines-

OECD Test Guidelines

TG 451 → Carcinogenicity study.

TG 452 → Chronic toxicity study.

TG 453 → Combined chronic toxicity + carcinogenicity.

ICH S1 → Guidance on rodent carcinogenicity testing of pharmaceuticals.

EPA → Carcinogenicity testing for pesticides, environmental chemicals.

Schedule Y (India) → Requires carcinogenicity testing for drugs used >6 months.

## Historical Background-

1950s–60s: Carcinogenicity testing became systematic after cancers caused by occupational exposures (benzidine, vinyl chloride).

1960s: FDA and NCI (National Cancer Institute, USA) developed rodent lifetime bioassays.

1970s–80s: OECD and ICH harmonized testing guidelines.

Current trend: Reduction of animal use → transgenic mice and in silico models.

## 4. General Study Design

### a. Test Species

Rodents (two species mandatory):

Rat → preferred (life span 2 years).

Mouse → second species (life span 18 months).

Sometimes non-rodents (dogs, monkeys) for special cases, but rarely.

### b. Grouping

50 animals/sex/dose group (large sample needed).

At least 3 dose levels + control.

### c. Dose Selection

High dose = Maximum Tolerated Dose (MTD) (produces mild toxicity but no major suffering).

Mid dose = ~50% of MTD.

Low dose = close to expected human exposure.

## d. Route of Administration

Same as intended human exposure: oral (most common), inhalation, dermal, injection.

## e. Duration

Rats → ~24 months (up to natural life span).

Mice → ~18 months.

Covers majority of the animal's life.

## f. Observations & Data

Clinical: Behavior, food intake, body weight, survival.

Pathology:

Gross necropsy of all organs.

Histopathology of tumors & non-tumor lesions.

Identification of benign vs malignant tumors.

# DEPTH OF BIOLOGY

Parameters recorded-

General health: food/water intake, weight, survival.

Clinical signs: behavioral changes, palpable tumors.

Necropsy: all organs examined post-mortem.

Histopathology: microscopic examination of tissues.

**Tumor data collected:**

Incidence (number of animals with tumors).

Multiplicity (tumors per animal).

Type: benign or malignant.

Organ specificity.

Latency (time of appearance).

## Step-wise Protocol -

Selection of species, strain, sex.

Randomization into groups.

Dose formulation and route of administration.

Daily/weekly dosing for 18–30 months.

Continuous monitoring for health, survival, tumors.

Interim sacrifices may be performed.

Final necropsy & histopathology.

Data analysis → tumor incidence, dose–response.

Risk assessment → extrapolate to human safety.

## 7. Advantages

Provides whole-animal data including metabolism, distribution, bioactivation, detoxification.

Detects organ-specific carcinogenicity.

Helps in human cancer risk assessment.

Forms the regulatory gold standard for carcinogenicity testing.

## 8. Limitations

Time-consuming: Requires 2–3 years.

Very costly: Needs large number of animals, high maintenance.

Species differences: Animal tumors may not predict human risk exactly.

Ethical issues: Long-term animal suffering.

High false positives/negatives: Due to species sensitivity.